Introduction {#S1}
============

Allergic rhinitis (AR) is a prevalent disease both in China and Western countries, affecting approximately 10--40% of people worldwide ([@B28]; [@B40]; [@B38]). Pathophysiologically, AR is an IgE-mediated type 2 inflammatory disorder caused by the interaction of airborne allergens. AR is characterized by inflammatory infiltrates, predominantly comprising eosinophils, mast cells, basophils, and T cells, which release granule proteins, cytokines, and chemokines to trigger the onset of clinical symptoms such as rhinorrhea, sneezing, nasal itching, and nasal congestion ([@B2]; [@B5]; [@B37]). AR severity is typically classified as either mild (M-AR) or moderate to severe (MS-AR) based on symptom severity according to Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines ([@B2]). Over half of AR patients are MS-AR, leading to significantly impaired normal daily activity ([@B3]; [@B29]). However, the mechanism driving the development of this form remains unclear.

Dendritic cells (DCs) are the most potent antigen-presenting cells; they play a pivotal role in the initiation of adaptive T cell immunity ([@B27]). In particular, myeloid DCs (mDCs), identified by the specific surface marker CD1c, are a major subset of DCs that preferentially activate and induce polarization of CD4^+^ T cells. Studies have indicated that mDCs are essential for the priming of Th2 cells, which are linked to anti-parasite immunity and are also associated with inappropriate response to innocuous antigens, triggering an allergic immune response ([@B21]; [@B24]; [@B8]; [@B15]). Accumulating evidence has revealed that signals from DCs play an essential role in Th2-cell polarization in allergic airway diseases ([@B8]; [@B15]; [@B33]). IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) are three innate cytokines that are mainly derived from epithelial cells. Previous studies have shown that this triad of cytokines plays a role in Th2 cell maturation through DC activation, thereby enhancing their Th2-polarizing capacity. For example, TSLP was able to activate human nasal mucosal CD1^+^ DCs and enhance their capacity to initiate Th2 responses ([@B22]). In a mouse model of ovalbumin-induced asthma, IL-25 was reported to promote DC activation, inducing naïve T cells to differentiate into pro-inflammatory Th2 cells ([@B12]). Upon exposure to IL-33, DCs exhibited increased protein expression of CD40 and OX40 ligand (OX40L), thereby potently inducing Th2 responses ([@B1]). Although these studies have demonstrated that IL-25, IL-33, and TSLP can independently develop type 2 immunity, more recent studies have shown that combined targeting of this cytokine triad is necessary for the suppression of progressive Th2-driven inflammation ([@B35]; [@B36]; [@B19]), suggesting that the functional activities of these three cytokines do not overlap.

Monocyte-derived DCs (mo-DCs), which can be generated from peripheral blood monocytes *in vitro* by 5--7 days of culture with GM-CSF and IL-4, have been regarded as an important source of inflammatory DCs during pathologic inflammation and closely simulate mDCs found in airway mucosa ([@B14]; [@B13]), thus providing a potent tool for the study of the role of mDC in allergic inflammation. Recently, we reported using this cell model that CD1c^+^ mo-DCs derived from AR patients expressed higher levels of IL-17RB (IL-25 receptor), ST2 (IL-33 receptor), and TSLPR (TSLP receptor) than healthy control (HC) subjects ([@B39]). However, the relative contribution and importance of each of these cytokines in directing the Th-polarizing function of DCs have yet to be conclusively established. The aim of this study was to determine the combined effect of IL-25, IL-33, and TSLP on DC function.

Materials and Methods {#S2}
=====================

Subjects {#S2.SS1}
--------

Volunteers with AR and healthy volunteers with no allergic or autoimmune disease symptoms were enrolled at Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, China, from November 2017 to March 2019. AR diagnosis was made according to ARIA guidelines. Atopic status was evaluated by the concentrations of serum IgE (ImmunoCAP, Phadia, Uppsala, Sweden) specific to local common inhalant allergens; e.g., house dust mites (HDMs), pets, pollens, molds, cockroaches, and so on ([@B18]). Concentrations above 0.7 IU/mL were considered positive. AR subjects mono-sensitized to HDMs and HC subjects negative to all allergens were screened. Subjects who received oral glucocorticoids, antihistamines, or immunotherapy, or had experienced acute upper and lower respiratory tract infection during the past month were excluded. A total of 15 AR and 10 HC subjects were included in this study; their characteristics are listed in [Table 1](#T1){ref-type="table"}. Peripheral blood samples for *in vitro* cell culture studies were collected from 10 AR and 10 HC subjects. Due to the limited amount of blood samples, not all samples were included in every study protocol. The 15 AR patients all underwent long-term follow-up as described below. This study was approved by the Ethics Committee of the First Affiliated Hospital, Sun Yat-sen University. All subjects provided written informed consent before participation. Standard biosecurity and institutional safety procedures were adhered to throughout the study.

###### 

Clinical characteristics of HC and AR subjects.

                                                     **HC subjects**   **AR subjects**   ***P*-value**                   
  -------------------------------------------------- ----------------- ----------------- --------------- ------- ------- ---------
  HDM-specific IgE (IU/mL), mean (SD)                0.14 (0.09)       28.42 (22.69)     54.82 (38.32)   0.024   0.013   0.036
  Blood EOS absolute number (× 10^9^/L), mean (SD)   0.11 (0.06)       0.21 (0.11)       0.34 (0.23)     0.042   0.007   0.043
  TNSS, median (IQR)                                 N/A               3 (1)             7 (2)           N/A     N/A     \<0.001

HC, healthy control; AR, allergic rhinitis; M-AR, mild AR; MS-AR, moderate to severe AR; HDM, house dust mite; EOS, eosinophil; TNSS, Total Nasal Symptom Score; SD, standard deviation; IQR, interquartile ranges; N/A, not applicable.

Follow-Up Study Design {#S2.SS2}
----------------------

Screening phase. At the time of screening (visit 1), all AR patients were asked to complete a Total Nasal Symptom Score (TNSS) questionnaire to assess disease severity.

Mild phase. AR was classified as M-AR when TNSS ≤ 4 and MS-AR when TNSS ≥ 5. Subjects were instructed to contact the study team if they experienced persistent M-AR for 2 weeks (visit 2).

Moderate to severe phase. A final visit (visit 3) occurred 2 weeks after transition into MS-AR.

Peripheral blood samples for specific IgE detection, blood routine testing, flow cytometry, and enzyme-linked immunosorbent assay (ELISA) were collected on visits 2 and 3.

TNSS {#S2.SS3}
----

The TNSS was completed by subjects based on a 1-week recall. Subjects were asked to assign scores that best reflected the intensity of nasal itching, sneezing, rhinorrhea, and nasal congestion caused by AR. Scoring criteria were as follows: 0, no symptoms; 1, occasional mild symptoms; 2, frequent moderate symptoms; and 3, continuous severe symptoms. The TNSS was calculated (range: 0--12) by summing the individual nasal scores.

Generation and Culture of DCs {#S2.SS4}
-----------------------------

To investigate the association of IL-17RB, ST2, and TSLPR on mDC with AR severity, peripheral blood mononuclear cells (PBMCs) were isolated for flow cytometry from whole-blood samples of HC, M-AR, and MS-AR subjects using the Ficoll-Hypaque gradient centrifugation technique, with erythrocytes removed using RBC Lysis Buffer (eBioscience, San Diego, CA, United States). CD1c^+^ cells were defined as mDCs.

Generation and culture of mo-DCs were performed as previously described ([@B13]). Briefly, CD14^+^ monocytes were positively sorted from PBMCs using the immunomagnetic cell sorting method with anti-CD14 antibody-coated magnetic beads (Miltenyi Biotec, Auburn, CA, United States). CD14^+^ cell purity was \> 95%, as confirmed by flow cytometry. To generate DCs, purified monocytes were cultured at a concentration of 5 × 10^5^ cells/mL for 5 days at 37°C in humidified air containing 5% CO~2~, in RPMI 1640 medium supplemented with heat-inactivated fetal bovine serum (FBS) (10%) and penicillin/streptomycin (1%) (all from Gibco, Carlsbad, CA, United States), in the presence of 50 ng/mL recombinant human (rh) granulocyte-macrophage colony-stimulating factor (GM-CSF; PeproTech Inc., Rocky Hill, NJ, United States) and 10 ng/mL rh IL-4 (R&D Systems, Minneapolis, MN, United States). Half of the medium was replaced every 2 days. CD14^--^CD1a^+^ cells were defined as DCs.

To investigate the effects of Toll-like receptor (TLR) ligands on DCs, mo-DCs were cultured for 48 h for flow cytometry in the presence of 300 ng/mL Pam3CSK4, 1 μg/mL PGN-BS, 10 μg/mL Poly I:C, 100 ng/mL FLA-ST, 100 ng/mL FSL-1, 2 μg/mL Imiquimod-R837, 500 ng/mL ssRNA40/LyoVecTM, and 7 μg/mL ODN2395 (all from InvivoGen, San Diego, CA, United States), or 1 μg/mL natural Dermatophagoides pteronyssinus allergen 1 (Der.p1) (Indoor Biotechnologies, Charlottesville, VA, United States). To investigate the combined effects of epithelial cell-derived cytokines on Der.p1-activated DCs, Der.p1-stimulated mo-DCs were further stimulated for 24 h for flow cytometry with different combinations of 10 ng/mL rhIL-25 (catalog no. 1258-IL), 10 ng/mL rhIL-33 (catalog no. 3625-IL), and 100 ng/mL TSLP (catalog no. 1398-TS) (all from R&D Systems).

Co-culture of DCs With CD4^+^ T Cells {#S2.SS5}
-------------------------------------

To investigate the combined effects of epithelial cell-derived cytokines on the T cell-polarizing function of DCs, on day 5, mo-DCs were stimulated for 48 h with 1 μg/mL Der.p1 (Indoor Biotechnologies), simultaneously with different combinations of blocking antibodies, namely, 2 μg/mL anti-IL-17RB (catalog no. MAB1207), 1 μg/mL anti-ST2 (catalog no. MAB523), and 1 μg/mL anti-TSLPR (catalog no. AF981) monoclonal antibodies (all from R&D Systems). Then, the mo-DCs were stimulated for an additional 24 h with different combinations of rhIL-25 (10 ng/mL), rhIL-33 (10 ng/mL), and rhTSLP (100 ng/mL) (all from R&D Systems), prior to co-culture with CD4^+^ T cells. On day 8, heterologous CD4^+^ T cells from PBMCs of HC subjects were positively purified by immunomagnetic cell sorting with anti-CD4 antibody-coated magnetic beads (Miltenyi Biotec) as previously described. The purity was \> 95%, as confirmed by flow cytometry. The CD69 expression on CD4^+^ T cells in PBMCs, as well as on freshly sorted CD4^+^ T cells, was confirmed by flow cytometry. Stimulated mo-DCs were washed twice with phosphate-buffered saline (PBS) and then co-cultured (5 × 10^4^ per well) with CD4^+^ T cells at a 1:10 DC/T-cell ratio in RPMI 1640 medium supplemented with FBS (10%) and penicillin/streptomycin (1%) (all from Gibco). After 5 days, cells and supernatants were harvested for flow cytometry and ELISA, respectively. For intracellular staining, co-cultured cells were re-stimulated with Cell Stimulation Cocktail (plus protein transport inhibitors) (eBioscience) for the final 5 h; the cocktail consisted of 81 nM phorbol 12-myristate 13-acetate and 1.34 μM ionomycin to stimulate cells to produce cytokines, as well as 10.6 μM brefeldin A and 2 μM monensin to block cytokines in the cytoplasm and enhance intracellular staining signals.

Flow Cytometry {#S2.SS6}
--------------

Cells were suspended in PBS with 0.5% bovine serum albumin (MP Biomedicals, Palm Springs, CA, United States) to prevent unspecific binding, and stained with a combination of florescence-conjugated antibodies. Prior to intracellular cytokine staining, cells were fixed and permeabilized with the Intracellular Fixation and Permeabilization Buffer Set (eBioscience). Detailed information on antibodies used in this study is provided in [Table 2](#T2){ref-type="table"}. Equal concentrations of species- and subtype-matched antibodies were used as negative controls. Flow cytometry was performed using a Gallios flow cytometer (Beckman Coulter), and data were analyzed using Kaluza Analysis v. 2.1 software (Kaluza Software, Fullerton, CA, United States).

###### 

Antibodies used for flow cytometry.

  **Antibody**   **Fluorochrome**   **Manufacturer**   **Clone**   **Source**
  -------------- ------------------ ------------------ ----------- ---------------------------
  CD1c           PerCp-Cy5.5        BD Biosciences     F10/21A3    Monoclonal Mouse IgG1, k
  CD86           APC                BD Biosciences     FUN-1       Monoclonal Mouse IgG1, k
  IL-17RB        PE                 R&D Systems        170220      Monoclonal Mouse IgG2b
  ST2            APC                R&D Systems        N/A         Polyclonal Goat IgG
  TSLPR          Alexa Fluor 700    R&D Systems        147036      Monoclonal Mouse IgG1
  OX40L          BV421              BD Biosciences     ik-1        Monoclonal Mouse IgG1, k
  PDL1           PE-Cy7             BD Biosciences     MIH1        Monoclonal Mouse IgG1, k
  ICOSL          PE                 BD Biosciences     2D3/B7-H2   Monoclonal Mouse IgG2b, k
  MHC-II         APC                eBioscience        LN3         Monoclonal Mouse IgG2b, k
  CD3            PE                 BD Biosciences     UCHT1       Monoclonal Mouse IgG1, k
  CD4            APC-Cy7            BD Biosciences     RPA-T4      Monoclonal Mouse IgG1, k
  IL-4           PerCp-Cy5.5        BD Biosciences     8D4-8       Monoclonal Mouse IgG1, k
  IL-5           FITC               R&D Systems        9906        Monoclonal Mouse IgG1
  IL-13          BV421              BD Biosciences     JES10-5A2   Monoclonal Rat IgG1
  IFN-γ          PE-Cy7             BD Biosciences     B27         Monoclonal Mouse IgG1, k
  IL-17A         AF647              BD Biosciences     SCPL1362    Monoclonal Mouse IgG1, k

ELISA {#S2.SS7}
-----

Cytokine levels in serum and cell culture supernatants were measured using commercial ELISA kits (R&D Systems) according to the manufacturer's instructions. Lower detection limits are listed in [Table 3](#T3){ref-type="table"}.

###### 

The lower detection limits for ELISA.

  **Cytokine**   **Lower detection level (pg/mL)**   **Source**
  -------------- ----------------------------------- -------------
  IL-4           31.2                                R&D Systems
  IL-5           4.7                                 R&D Systems
  IL-13          93.8                                R&D Systems

Statistical Analyses {#S2.SS8}
--------------------

PBMC flow cytometry data and serum ELISA data were tested for normality using the Shapiro--Wilk test; data are expressed as means ± standard deviation, or medians with interquartile range according to normality test results. *In vitro* cell culture data are expressed as means ± standard deviation. We used Student's *t*-test, Mann--Whitney *U-*test, paired *t-*test, or Wilcoxon matched pair signed rank test to assess significant differences among groups. Correlations were analyzed using the Spearman's rank correlation coefficient. Statistical significance was evaluated at a level of *P* \< 0.05.

Results {#S3}
=======

TLR Ligands Induced AR-Derived mo-DCs to Express IL-17RB, ST2, and TSLPR {#S3.SS1}
------------------------------------------------------------------------

We first extended our recent study ([@B13]) to explore the effects of TLR ligands other than lipopolysaccharide (LPS) on expression of IL-17RB, ST2, and TSLPR on mo-DCs. In HC-derived mo-DCs, IL-17RB upregulation was observed only with Pam3CSK4, PGN-BS, PLA-ST, and FSL-1 treatment, whereas all TLR ligands tested did not affect ST2 or TSLPR expression ([Figures 1B,D](#F1){ref-type="fig"}). By contrast, all TLR ligands upregulated IL-17RB, ST2, and TSLPR expression on AR-derived mo-DCs by varying degrees; the sole exception was the effect of FSL-1 on TSLPR expression ([Figures 1A,C](#F1){ref-type="fig"}). Der.p1 was the strongest inducer of IL-17RB, ST2, and TLSPR upregulation ([Figures 1A,C](#F1){ref-type="fig"}). The mean percentages of IL-17RB^+^, ST2^+^, and TSLPR^+^ cells in Der.p1-induced mo-DCs were 70.25, 18.67, and 87.13%, respectively ([Figure 1A](#F1){ref-type="fig"}). Der.p1-induced mo-DCs also appeared to express the highest level of co-expression of IL-17RB, ST2, and TSLPR (∼4.64% of Der.p1-induced mo-DCs), compared with the counterparts of other TLR ligand-induced mo-DCs ([Figure 1E](#F1){ref-type="fig"}).

![TLR ligands induced allergic rhinitis (AR)-derived monocyte-derived DCs (mo-DCs) to express IL-17RB, ST2, and thymic stromal lymphopoietin (TSLPR). **(A,B)** Representative flow plots of IL-17RB, ST2, and TSLPR expression on CD1c^+^ mo-DCs derived from AR (*n* = 9) and healthy control (HC) (*n* = 6) subjects before and 48 h after stimulation with Pam3CSK4, PGN-BS, Poly I:C, Der.p1, FLA-ST, FSL-1, Imiquimod-R837, ssRNA, and ODN2395. Gray histograms were negative isotypes. **(C,D)** Quantification of percentages of IL-17RB^+^, ST2^+^, and TSLPR^+^ cells in CD1c^+^ mo-DCs derived from AR and HC subjects. **(E)** Quantification of percentages of IL-17RB^+^ST2^+^TSLPR^+^ cells in CD1c^+^ mo-DCs derived from AR subjects. Data are expressed as means ± standard deviation (SD). Significant differences were tested using the paired *t*-test between control and TLR groups, and using Student's *t*-test between TLR stimulation groups. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](fcell-08-00207-g001){#F1}

Phenotypic Characteristics of HDM-Induced mo-DCs {#S3.SS2}
------------------------------------------------

We further characterized the phenotype of Der.p1-induced mo-DCs. We found that Der.p1 upregulated CD86 expression on mo-DCs derived from both HC and AR subjects ([Figures 2A,B](#F2){ref-type="fig"}). However, Der.p1 increased OX40L expression on mo-DCs derived from AR, but not HC subjects ([Figures 2C,D](#F2){ref-type="fig"}). In addition, Der.p1 did not affect the expression of PDL1 or ICOSL on mo-DCs from HC or AR subjects ([Figures 2C,D](#F2){ref-type="fig"}).

![Phenotypic characteristics of house dust mite (HDM)-induced mo-DCs. **(A)** Representative flow plots of CD86 expression on CD1c^+^ mo-DCs derived from AR (*n* = 9) and HC (*n* = 6) subjects before and 48 h after stimulation with Der.p1. Gray histograms were negative isotypes. **(B)** Quantification of percentages of CD86^+^ cells in CD1c^+^ mo-DCs. **(C)** Representative flow plots of OX40L, PDL1, and ICOSL expression on CD1c^+^ mo-DCs derived from AR (*n* = 9) and HC (*n* = 6) subjects before and 48 h after stimulation with Der.p1. **(D)** Quantification of percentages of OX40L^+^, PDL1^+^, and ICOSL^+^ cells in CD1c^+^ mo-DCs. Data are expressed as means ± SD, and tested using the paired *t*-test. \*\*\**P* \< 0.001.](fcell-08-00207-g002){#F2}

Effects of IL-25, IL-33, and TSLP on the mo-DC Phenotype {#S3.SS3}
--------------------------------------------------------

We next determined the effects of IL-25, IL-33, and TSLP on the phenotype of Der.p1-induced mo-DCs cultured in the presence of IL-25, IL-33, and TSLP, alone or in combination. We observed no significant change in HLA-DR or CD86 expression on mo-DCs from HC or AR subjects cultured with IL-25, IL-33, and TSLP, singly or in combination, compared with those without IL-25, IL-33, and TSLP treatment ([Figures 3A--D](#F3){ref-type="fig"}). Interestingly, increased OX40L expression was observed on AR-derived mo-DCs cultured in the presence of IL-25, IL-33, and TSLP, either alone or in double combination, compared with those cultured in the absence of IL-25, IL-33, and TSLP ([Figures 3A,C](#F3){ref-type="fig"}). Surprisingly, mo-DCs cultured with a triple combination of IL-25, IL-33, and TSLP showed further enhanced OX40L expression ([Figures 3A,C](#F3){ref-type="fig"}). We did not observe similar results on HC-derived mo-DCs ([Figures 3B,D](#F3){ref-type="fig"}).

![Effects of IL-25, IL-33, and TSLP on the phenotype of mo-DCs. **(A,B)** Representative flow plots of HLA-DR, CD86, and OX40L expression on Der.p1-induced mo-DCs from AR (*n* = 7) and HC (*n* = 8) subjects cultured in the presence of IL-25, IL-33, and TSLP, singly or in combination, for 24 h. Gray histograms were negative isotypes. **(C,D)** Quantification of percentages of HLA-DR^+^, CD86^+^, and OX40L^+^ cells in Der.p1-induced mo-DCs. Data are expressed as means ± SD. Significant differences were tested using the paired *t*-test between control and cytokine stimulation groups, and using Student's *t*-test between cytokine stimulation groups. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](fcell-08-00207-g003){#F3}

Effects of IL-25, IL-33, and TSLP on the Pro-Th2 Function of AR-Derived mo-DCs {#S3.SS4}
------------------------------------------------------------------------------

We next focused on the effects of the cytokine triad on the function of AR-derived mo-DCs induced by Der.p1. The mo-DCs were stimulated with IL-25, IL-33, and TSLP, alone or in combination, for 24 h, and then co-cultured with CD4^+^ T cells sorted from HC subjects for 5 days. No significant change in CD69 expression on the sorted CD4^+^ T cells was observed compared with their counterparts in PBMCs ([Figure 4](#F4){ref-type="fig"}). We found that IL-25, IL-33, and TSLP, alone or in double combination, significantly increased the production of Th2 cytokines including IL-4, IL-5, and IL-13, both intracellularly, as evaluated by flow cytometry ([Figures 5A,B](#F5){ref-type="fig"}), and extracellularly, as measured by ELISA ([Figure 5C](#F5){ref-type="fig"}). IL-4, IL-5, and IL-13 responses were further enhanced when mo-DCs were stimulated with a triple combination of IL-25, IL-33, and TSLP ([Figures 5A--C](#F5){ref-type="fig"}). However, we observed no significant change in IFN-γ or IL-17A production in CD4^+^ T cells between mo-DCs treated with or without IL-25, IL-33, and TLSP, alone or in combination ([Figure 6](#F6){ref-type="fig"}).

![Freshly sorted CD4^+^ T cells from HC subjects were not activated. **(A,B)** Representative flow plots of CD69 expression on CD4^+^ T cells in peripheral blood mononuclear cells (PBMCs) and on freshly positively sorted CD4^+^ T cells from HC subjects (*n* = 8). **(C)** Quantification of percentages of CD69^+^ cells in CD4^+^ T cells in PBMCs and in sorted CD4^+^ T cells. Data were tested for normality using the Shapiro--Wilk test, and expressed as means ± SD according to normality test results. Significant difference was tested using paired *t*-test between groups.](fcell-08-00207-g004){#F4}

![Effects of IL-25, IL-33, and TSLP on the pro-Th2 function of AR-derived mo-DCs. **(A)** Representative flow plots of IL-4, IL-5, and IL-13 expression by CD4^+^ T cells from HC subjects (*n* = 8) co-cultured for 5 days with Der.p1-induced mo-DCs from AR subjects (*n* = 8). Prior to co-culturing, Der.p1-induced mo-DCs were stimulated with IL-25, IL-33, and TSLP, singly or in combination, for 24 h. **(B)** Quantification of percentages of IL-4^+^, IL-5^+^, and IL-13^+^ cells in CD4^+^ T cells. **(C)** Protein levels of IL-4, IL-5, and IL-13 in the supernatants of co-cultured cells as measured by ELISA (*n* = 6). Data are expressed as means ± SD. Significant differences were tested using the paired *t*-test between control and cytokine stimulation groups, and using Student's *t*-test between cytokine stimulation groups. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](fcell-08-00207-g005){#F5}

![IL-25, IL-33, and TSLP had no effect on the pro-Th1/Th17 function of AR-derived mo-DCs. **(A)** Representative flow plots of IFN-γ and IL-17 expression by CD4^+^ T cells from HC subjects (*n* = 8) co-cultured for 5 days with Der.p1-induced mo-DCs from AR subjects (*n* = 8). Prior to co-culture, Der.p1-induced mo-DCs were stimulated with IL-25, IL-33, and TSLP, singly or in combination, for 24 h. **(B)** Quantification of percentages of IFN-γ^+^ and IL-17^+^ cells in CD4^+^ T cells. Data are expressed as means ± SD. Significant differences were tested using the paired *t*-test between control and cytokine stimulation groups, and using Student's *t*-test between cytokine stimulation groups.](fcell-08-00207-g006){#F6}

To further confirm the combined pro-Th2 effect of IL-25, IL-33, and TSLP, we used anti-IL-17RB, anti-ST2, and anti-TSLPR on day 5, alone or in combination, together with Der.p1 stimulation, to block IL-25, IL-33, and TSLP signals. As expected, when signals from the triad of cytokines were blocked singly or in double combination, IL-4, IL-5, and IL-13 responses were impaired ([Figures 7A--C](#F7){ref-type="fig"}). However, the decreases in Th2 cytokine level were similar between those blocked singly and in double combination ([Figures 7A--C](#F7){ref-type="fig"}). Only when the triad of cytokine signals was blocked in triple combination were IL-4, IL-5, and IL-13 responses suppressed to negative control levels ([Figures 7A--C](#F7){ref-type="fig"}).

![Combined pro-Th2 effects of IL-25, IL-33, and TSLP on AR-derived mo-DCs. **(A)** Representative flow plots of IL-4, IL-5, and IL-13 expression by CD4^+^ T cells co-cultured for 5 days with Der.p1-induced mo-DCs from AR subjects (*n* = 8). Prior to co-culture, mo-DCs were induced by Der.p1 in the presence of anti-IL-17RB, anti-ST2, and anti-TSLPR blocking antibodies, singly or in combination, for 48 h, and then further stimulated with combined IL-25, IL-33, and TSLP for 24 h. **(B)** Quantification of percentages of IL-4^+^, IL-5^+^, and IL-13^+^ cells in CD4^+^ T cells. **(C)** Protein levels of IL-4, IL-5, and IL-13 in the supernatants of co-cultured cells, as measured by ELISA (*n* = 6). Data are expressed as means ± SD. Significant differences were tested using the paired *t*-test between control and antibody blocking groups, and using Student's *t*-test between antibody blocking groups. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](fcell-08-00207-g007){#F7}

IL-17RB, ST2, and TSLPR Upregulation in Myeloid DCs Was Associated With AR Severity {#S3.SS5}
-----------------------------------------------------------------------------------

Since Der.p1 was shown to best induce IL-17RB, ST2, and TSLPR expression on AR-derived mo-DCs ([Figure 1](#F1){ref-type="fig"}), we next explored whether DC expression of these receptors was associated with disease severity in patients with HDM-sensitive AR. M-AR patients were enrolled and followed up for disease exacerbation ([Figure 8A](#F8){ref-type="fig"}). As expected, IL-4, IL-5, and IL-13 responses were elevated in patients with AR, as measured by intracellular flow cytometry and ELISA ([Figures 8B--D](#F8){ref-type="fig"}). Despite worsening of patient symptoms from M-AR to MS-AR, IL-4, IL-5, and IL-13 responses were further enhanced ([Figures 8B--D](#F8){ref-type="fig"}). Correlation analysis showed that percentages of IL-4^+^, IL-5^+^, and IL-13^+^ T cells were positively correlated with TNSS in AR patients (*r* = 0.596, *P* = 0.001; *r* = 0.398, *P* = 0.030; and *r* = 0.412, *P* = 0.024, respectively) ([Figure 8E](#F8){ref-type="fig"}). We observed no significant difference in IFN-γ and IL-17A responses, as measured by intracellular flow cytometry between AR and HC subjects. Interestingly, we observed elevated IFN-γ production in CD4^+^ T cells among MS-AR patients compared with M-AR patients ([Figures 8B,C](#F8){ref-type="fig"}).

![Enhanced Th2 response, but not IL-25, IL-33, and TSLP levels, was associated with disease exacerbation in AR patients. **(A)** Flow diagram for follow-up study of AR patients. **(B)** Representative flow plots of IL-4, IL-5, IL-13, IFN-γ, and IL-17 expression by CD4^+^ T cells in PBMCs from AR subjects in both mild phase (M-AR) (*n* = 15) and moderate to severe phase (MS-AR) (*n* = 15), and HC (*n* = 10) subjects. **(C)** Quantification of percentages of IL-4^+^, IL-5^+^, IL-13^+^, IFN-γ^+^, and IL-17^+^ cells in CD4^+^ T cells in PBMCs. **(D)** Protein levels of IL-4, IL-5, and IL-13 in serum of AR (*n* = 15) and HC (*n* = 10) subjects, as measured by ELISA. Data were tested for normality using the Shapiro--Wilk test, and expressed as means ± SD or medians with interquartile range (IQR), according to normality test results. Significant differences were tested using Student's *t*-test or the Mann--Whitney *U* test between HC and AR groups, and using the paired *t*-test or Wilcoxon matched pairs signed rank test between M-AR and MS-AR groups. **(E)** Correlation of Total Nasal Symptom Score (TNSS) with percentage of IL-4^+^, IL-5^+^, and IL-13^+^ T cells in PBMCs among M-AR and MS-AR patients (*n* = 30) were analyzed using Spearman's rank correlation coefficient (*r* = 0.596, *P* = 0.001, 1--β = 0.952; *r* = 0.398, *P* = 0.030, 1--β = 0.604; and *r* = 0.412, *P* = 0.024, 1--β = 0.638, respectively). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](fcell-08-00207-g008){#F8}

We next detected IL-17RB, ST2, and TSLPR expression levels on CD1c^+^ mDCs in peripheral blood. As shown by flow cytometry, the percentage of mDCs in PBMCs was elevated in MS-AR patients, but not in M-AR patients, compared with HC subjects ([Figures 9A,B](#F9){ref-type="fig"}). IL-17RB levels on mDCs were increased in both M-AR and MS-AR patients ([Figures 9C,D](#F9){ref-type="fig"}). IL-17RB levels on mDCs of MS-AR patients were significantly higher than those of M-AR patients ([Figures 9C,D](#F9){ref-type="fig"}). ST2 levels on mDCs were increased in MS-AR patients, but not in M-AR patients, compared with HC subjects. The percentage of TSLPR^+^ cells in mDCs was as high as 80% in both M-AR and MS-AR patients, which was significantly higher than that of HC subjects ([Figures 9C,D](#F9){ref-type="fig"}). IL-17RB^+^ mDCs in MS-AR patients, but not M-AR patients, expressed higher OX40L levels than HC subjects ([Figure 9E](#F9){ref-type="fig"}). In addition, both ST2^+^ mDCs and TSLPR^+^ mDCs in M-AR and MS-AR patients expressed higher OX40L levels than HC subjects ([Figure 9E](#F9){ref-type="fig"}).

![Upregulation of IL-17RB, ST2, and TSLPR on myeloid DCs (mDCs) was associated with AR disease severity. **(A)** Representative flow plots of the percentage of CD1c^+^ cells in PBMCs from M-AR (*n* = 15), MS-AR (*n* = 15), and HC (*n* = 10) subjects. **(B)** Quantification of the percentage of CD1c^+^ cells in PBMCs. **(C)** Representative flow plots of the percentage of IL-17RB^+^, ST2^+^, TSLPR^+^, and OX40L^+^ cells in CD1c^+^ mDCs of PBMCs from M-AR (*n* = 15), MS-AR (*n* = 15), and HC (*n* = 10) subjects. **(D)** Quantification of percentages of IL-17RB^+^, ST2^+^, and TSLPR^+^ cells in CD1c^+^ mDCs of PBMCs. **(E)** Quantification of OX40L expression in IL-17RB^+^, ST2^+^, and TSLPR^+^ mDCs in PBMCs. **(F)** Quantification of the percentage of IL-17RB^+^ST2^+^TSLPR^+^ cells in CD1c^+^ mDCs of PBMCs. Data were tested for normality using the Shapiro--Wilk test, and expressed as means ± SD or medians with IQR, according to normality test results. Significant differences were tested using Student's *t*-test or the Mann--Whitney *U-*test between HC and AR groups, and using the paired *t*-test or Wilcoxon matched pairs signed rank test between M-AR and MS-AR groups. **(G)** Correlation of the percentage of IL-17RB^+^ST2^+^TSLPR^+^ mDCs with that of IL-4^+^, IL-5^+^, and IL-13^+^ T cells in PBMCs of M-AR and MS-AR patients (*n* = 30) were analyzed using Spearman's rank correlation coefficient (*r* = 0.601, *P* \< 0.001, 1--β = 0.956; *r* = 0.591, *P* = 0.001, 1--β = 0.948; and *r* = 0.424, *P* = 0.019, 1--β = 0.667, respectively). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](fcell-08-00207-g009){#F9}

We further analyzed IL-17RB, ST2, and TLSPR co-expression on mDCs and explored their correlation with the Th2 response. The results showed that the percentage of mDCs co-expressing IL-17RB, ST2, and TSLPR was significantly increased in both M-AR and MS-AR patients compared with that of HC subjects ([Figure 9F](#F9){ref-type="fig"}). The percentage of mDCs co-expressing IL-17RB, ST2, and TSLPR was significantly higher in MS-AR patients than in M-AR patients ([Figure 9F](#F9){ref-type="fig"}). Correlation analysis showed that the percentage of IL-17RB^+^ST2^+^TSLPR^+^ mDCs was positively correlated with that of IL-4^+^, IL-5^+^, and IL-13^+^ T cells in AR patients (*r* = 0.601, *P* \< 0.001; *r* = 0.591, *P* = 0.001; and *r* = 0.424, *P* = 0.019, respectively) ([Figure 9G](#F9){ref-type="fig"}).

Discussion {#S4}
==========

TSLP, IL-25, and IL-33 are three epithelial-derived innate cytokines that have been independently reported to be activators of type 2 immunity ([@B7]; [@B31]; [@B30]; [@B4]; [@B6]; [@B11]). However, their potency as standalone stimulators of DCs or their potential mutual redundancy remains unclear. Since DCs closely underlie the mucosa epithelium ([@B9]), a better understanding of the potency of this triad of epithelial-derived cytokines as DC activators could be critical when selecting the most efficacious therapeutic targets for atopic diseases such as AR and asthma.

Recently, we demonstrated that IL-17RB^+^ mo-DCs derived from AR patients can be induced by LPS, and displayed enhanced pro-Th2 function following IL-25 stimulation ([@B39]). In the current study, we used the same methodology to rapidly generate immature DCs from peripheral blood monocytes, and found that nine human TLR1--9 ligands were all able to upregulate IL-17RB, ST2, and TSLPR by varying degrees on immature mo-DCs generated from AR patients sensitized to HDMs. Der.p1 showed the strongest induction of IL-17RB, ST2, and TSLPR. Using AR-derived mo-DCs, we found that, although individual activation of IL-17RB, ST2, and TSLPR potentiated the Th2-polarizing function of AR-derived mo-DCs, triple combinatorial activation was more efficacious than activating any of these receptors alone or in double combination. Interestingly, we detected no significant difference when the receptors were activated alone or in double combination. IL-17RB, ST2, and TSLPR levels were upregulated in mDCs in AR patients and associated with disease severity. Together, these data reveal that the pro-Th2 function of DCs derived from AR patients by combinatorial activation of IL-17RB, ST2, and TSLPR signaling is superior to that by single or double activation, suggesting that aggressive triple targeting of these receptors may more effectively inhibit DC-driven type 2 inflammation in patients with AR.

It has been reported that IL-17RB, ST2, and TSLPR can be expressed on a variety of immune cells such as innate lymphoid cells ([@B10]; [@B32]), T cells ([@B23]; [@B26]; [@B20]), and DCs ([@B16]; [@B34]; [@B25]; [@B39]). DC expression of these receptors has been described in our previous work and by others as being related to DC-driven type 2 immune responses ([@B16]; [@B34]; [@B25]; [@B39]). However, little is known about the regulation and function of DC expression of these receptors in allergic diseases. In the present study, we showed that mo-DCs derived from AR patients, but not HCs, upregulated IL-17RB, ST2, and TSLPR expression in response to TLR ligands, including those for TLR1--9. In addition, OX40L, a costimulatory molecule of the TNF ligand family, which has been described on the surfaces of DCs as supporting a Th2-skewed immune response ([@B16]; [@B17]), was increased only on AR-derived mo-DCs in response to Der.p1 stimulation. We confirmed *in vivo* that CD1c^+^ DCs in PBMCs of AR patients expressed higher IL-17RB, ST2, and TSLPR levels than their HC counterparts, which is consistent with our previous report ([@B39]). Levels of CD1c^+^ DCs coexpressing IL-17RB, ST2, and TSLPR were positively correlated with those of Th2 cells in PBMCs. Together, these results suggest that DC expression of IL-17RB, ST2, and TSLPR may be involved in the regulation of Th2 inflammation in AR patients.

Although previous studies have identified critical roles for TSLP, IL-25, and IL-33 as important initiators of the type 2 response or inflammation, few studies have addressed their overlapping effects, particularly on the T cell-polarizing function of DCs. In mouse models of allergen-induced airway inflammation and acute pulmonary fibrosis, individual blockade of IL-25, IL-33, or TSLP was shown to have little influence on Th2-mediated pulmonary fibrosis, whereas blockade of all three cytokines significantly reduced inflammation, ILC2 recruitment, eosinophilia, and fibrosis in the lung, suggesting that combined targeting may be required to temper type 2-driven inflammation ([@B36]). In another study using a food allergy mouse model, blockade of IL-25, IL-33, or TSLP did not suppress established food allergies, and optimal food allergy suppression required treatment by combined blocking of all three cytokine signals ([@B19]). In the current study, we found that collective activation of IL-17RB, ST2, and TSLPR on AR-derived mo-DCs resulted in a stronger Th2 response than their single or double-combination activation, suggesting that successful inhibition of cytokine triad-elicited Th2 inflammation would require inhibition of all three cytokine signals or suppression of the production of all three cytokines. This hypothesis was further supported by the results of an *in vitro* blocking experiment showing that inhibition of the Th2 response elicited by collective activation of IL-17RB, ST2, and TSLPR on AR-derived mo-DCs required the blocking of all three signals.

Although we have provided new information that combinatorial activation of IL-17RB, ST2, and TSLPR on DCs results in more potent promotion of the Th2 response, several limitations must be addressed before more definitive conclusions can be drawn. The major limitation of this finding is that it lacks an *ex vivo* study. This limitation may be addressed in future work through DC adoptive transfer experiments. In addition, because the DCs used in the present study were induced from peripheral blood monocytes, which are unable to represent distinct DC subsets such as myeloid or plasmoid DCs, the roles of IL-17RB, ST2, and TSLPR in the function of different DC subsets remain to be investigated.

In summary, we demonstrated that AR-derived mo-DCs activated by triple combination of IL-17RB, ST2, and TSLPR have a stronger capacity to elicit the Th2 response than those activated singly or in double combination. Additionally, mDCs in PBMCs of AR patients express higher levels of IL-17RB, ST2, and TSLPR, in a manner positively correlated with disease severity and Th2 cell levels in peripheral blood, suggesting that the Th2 response amplification function of DCs by combinatorial IL-17RB, ST2, and TSLPR signaling is associated with AR severity.
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